Jenscare Scientific Co., Ltd. was formally established on November 8, 2011

We initiated the research and development of Ken-Valve, AnchorValve, LuX-Valve and MitraPatch

Our technology “animal-derived tissues or organs immunogenicity elimination and anti-calcification value technologies” was enlisted in the National Key Research and Development Program of the Ministry of Science and Technology

We initiated the research and development of KenFlex

We completed the implantation of LuX-Valve and Ken-Valve in the first human subject

We initiated the research and development of LuX-Valve Plus

We completed our Series A Financing and raised RMB50 million

LuX-Valve was admitted into the Green Path by the NMPA

We initiated the multi-center feasibility clinical trial for Ken-Valve

LuX-Valve, was awarded the second prize in the China Innovation and Entrepreneurship Competition in October

LuX-Valve was a finalist in the TCT Shark Tank competition globally, being the first Chinese product to be enlisted in this competition

We initiated the research and development of JensT-Clip and JensClip

We completed the multi-center feasibility clinical trial for LuX-Valve

We were awarded the Subramanian Innovation Award by the International Society for Minimally Invasive Cardiothoracic Surgery (“ISMICS”)

We completed the Equity Swap and Ningbo DioChange became our wholly-owned subsidiary under merger accounting, which developed our business in heart failure

We initiated the confirmatory clinical trial for LuX-Valve

We completed our Series B Financing and raised RMB400 million

We initiated the confirmatory clinical trial for Ken-Valve

We completed our Series C Financing and raised USD163,636,30. We introduced a number of internationally renowned professional investors

We completed the subject enrollments of confirmatory clinical trials of LuX-Valve

LuX-Valve was designated as a Breakthrough Device by U.S. FDA

We are in the process of initiating the clinical trial for LuX-Valve Plus for CE Marking in Europe

We initiated the feasibility clinical trial for JensClip in China

Procedures implementing LuX-Valve Plus have also been successfully performed at St. Paul's Hospital in Canada on eleven subjects

Procedures implementing LuX-Valve Plus have been successfully performed for the first time in Europe at the University Hospital of Bordeaux in France, followed by another such procedure successfully performed in Germany

We completed the subject enrollments of confirmatory clinical trial of Ken-Valve

LuX-Valve's registration application was accepted by NMPA as scheduled, and entered registration review stage successfully

LuX-Valve Plus completed confirmatory clinical trial; is under enrollment of CE registration clinical trail; submitted pre-submission for EFS and was accepted by FDA

LuX-Valve Plus was selected into Total Product Life Cycle Advisory Program (TAP) by FDA

LuX-Valve Plus was selected for Expert Panel Scientific Advice Pilot in Europe by EMA

LuX-Valve Plus has completed a number of pre-commercial activities in North America and Asia-Pacific regions

Ken-Valve entered registration review stage successfully, realized the one and only valve product being selected for the NMPA priority approval process

JensClip completed feasibility clinical trial and is under enrollment of confirmatory clinical enrollment

SimuLock completed its first enrollment of NMPA confirmatory clinical trial

OmniSeal completed its first clinical implantation

LuX-Valve Plus has completed all the subject enrollments for the clinical trial carried out in Europe with the aim of obtaining the CE Certificate
LuX-Valve Plus has entered the clinical trial stage in the U.S.
LuX-Valve Plus has completed the one-year follow-up of the registration clinical trial in Mainland China
LuX-Valve Plus has completed a large number of pre-commercial activities worldwide
JensClip has completed the enrollment for confirmatory clinical trial and six-month follow-up 

LuX-Valve Plus is under registration review stage in mainland China, the multicenter registration clinical trial is in the long-term follow-up phase; RCT (randomized controlled trial) of OMT has completed subject enrollment
LuX-Valve Plus is under registration review for CE Marking in Europe; and has completed the 6-months follow-up of the global multicenter clinical trial TRINITY Study
LuX-Valve Plus completed FDA IDE EFS subject enrollment in U.S., received reimbursement from CMS for device and related expenses; and is in preparation for Pivotal Study
Ken-Valve obtained registration approval from NMPA and has realized a series of commercial implantation cases
JensClip has submitted its NMPA registration application
JensClip has submitted its registration application for CE mark